M J Murphy1, J M Newby1,2, P Butow3, S A Loughnan1, A E Joubert1, L Kirsten3,4, K Allison3, J Shaw3, H L Shepherd3, J Smith1, G Andrews1. 1. Clinical Research Unit for Anxiety and Depression, UNSW, NSW, Australia. 2. School of Psychology, Faculty of Science, UNSW, NSW, Australia. 3. Psycho-oncology Co-operative Research Group, University of Sydney, NSW, Australia. 4. Nepean Cancer Care Centre, NSW, Australia.
Abstract
PURPOSE: To evaluate internet-delivered cognitive behavioural therapy (iCBT) on clinical depression and/or anxiety, distress, fear of cancer recurrence, and quality of life in cancer survivors. METHODS: Random assignation of 114 participants to iCBT or treatment-as-usual (TAU). The clinician-supervised iCBT program (iCanADAPT Early) consisted of eight lessons over 16 weeks. Self-report questionnaires occurred at baseline, midpoint, and posttreatment for both groups with 3-month follow-up for iCBT participants. A mixed modelling approach to compare groups occurred. RESULTS:iCBT was superior to TAU on all outcome measures at posttreatment. Compared with TAU, the iCBT group showed a significant decrease over time in anxiety and depression symptoms (primary outcome, Hospital Anxiety and Depression Scale, Hedges g = 1.51). Additionally the iCBT group had significantly lower general distress (Kessler-10, g = 1.56), fear of cancer recurrence (Fear of Cancer Recurrence Inventory, g = 0.39), and significantly higher quality of life (Functional Assessment of Cancer Therapy-General, g = 0.74) at posttreatment compared with the TAU group. High adherence and satisfaction were found for iCBT with low clinician time. CONCLUSION: Clinician-supervised iCBT has significant benefits for cancer survivors with clinical depression and anxiety disorders.
RCT Entities:
PURPOSE: To evaluate internet-delivered cognitive behavioural therapy (iCBT) on clinical depression and/or anxiety, distress, fear of cancer recurrence, and quality of life in cancer survivors. METHODS: Random assignation of 114 participants to iCBT or treatment-as-usual (TAU). The clinician-supervised iCBT program (iCanADAPT Early) consisted of eight lessons over 16 weeks. Self-report questionnaires occurred at baseline, midpoint, and posttreatment for both groups with 3-month follow-up for iCBT participants. A mixed modelling approach to compare groups occurred. RESULTS: iCBT was superior to TAU on all outcome measures at posttreatment. Compared with TAU, the iCBT group showed a significant decrease over time in anxiety and depression symptoms (primary outcome, Hospital Anxiety and Depression Scale, Hedges g = 1.51). Additionally the iCBT group had significantly lower general distress (Kessler-10, g = 1.56), fear of cancer recurrence (Fear of Cancer Recurrence Inventory, g = 0.39), and significantly higher quality of life (Functional Assessment of Cancer Therapy-General, g = 0.74) at posttreatment compared with the TAU group. High adherence and satisfaction were found for iCBT with low clinician time. CONCLUSION: Clinician-supervised iCBT has significant benefits for cancer survivors with clinical depression and anxiety disorders.
Authors: Johanna Graf; Martin Teufel; Alexander Bäuerle; Peter Martus; Yesim Erim; Caterina Schug; Jana Heinen; Julia Barbara Krakowczyk; Jasmin Steinbach; Mirjam Damerau; Wolfgang Bethge; Andreas Dinkel; Sebastian Dries; Anja Mehnert-Theuerkauf; Anja Neumann; Dirk Schadendorf; Mitra Tewes; Jörg Wiltink; Alexander Wünsch; Stephan Zipfel Journal: BMJ Open Date: 2022-06-01 Impact factor: 3.006
Authors: Anna Hauffman; Sven Alfonsson; Anna Bill-Axelson; Leif Bergkvist; Marina Forslund; Susanne Mattsson; Louise von Essen; Peter Nygren; Helena Igelström; Birgitta Johansson Journal: Psychooncology Date: 2020-09-22 Impact factor: 3.894